Apple’s Legal Triumph: Masimo’s Patent Claims Dismissed, Paving Way for Unrestricted Apple Watch Sales
In a significant legal victory for Apple, the prolonged patent dispute with medical technology company Masimo has reached a pivotal conclusion. The U.S. District Court for the District of Columbia has dismissed Masimo’s complaint against the United States International Trade Commission (ITC) and U.S. Customs and Border Protection with prejudice, effectively closing this chapter of litigation and removing the immediate threat of an Apple Watch import ban in the United States.
Background of the Dispute
The legal battle commenced in 2020 when Masimo accused Apple of infringing on its pulse oximetry technology patents, specifically targeting the blood oxygen monitoring feature introduced in the Apple Watch Series 6. Masimo alleged that Apple had misappropriated its proprietary technology, leading to a series of legal confrontations over the ensuing years.
Key Developments in the Legal Proceedings
– Patent Infringement Allegations: Masimo’s initial lawsuit claimed that Apple’s integration of blood oxygen monitoring in its smartwatches violated Masimo’s patents. This led to a series of legal actions, including a notable $634 million verdict against Apple in November 2025, where a federal jury found Apple guilty of patent infringement related to the Apple Watch’s blood oxygen-sensing technology. ([macrumors.com](https://www.macrumors.com/2025/11/15/apple-634-million-verdict-masimo-lawsuit/?utm_source=openai))
– Import Ban and Product Modifications: In December 2023, the ITC imposed an import ban on certain Apple Watch models, including the Series 9 and Ultra 2, due to the alleged patent violations. In response, Apple modified these models by disabling the blood oxygen monitoring feature for U.S. consumers to comply with the ruling. ([tomsguide.com](https://www.tomsguide.com/wellness/fitness/the-apple-watch-blood-oxygen-ban-is-over-heres-what-it-means-for-apple-watch-wearers?utm_source=openai))
– Legal Appeals and Redesigns: Apple appealed the ITC’s decision and introduced redesigned Apple Watch models with alterations to the blood oxygen feature. In March 2026, an Administrative Law Judge ruled that these redesigned models did not infringe on Masimo’s patents. The ITC’s decision not to review this ruling on April 17, 2026, made the redesign approval final and terminated the enforcement proceedings. ([medtechdive.com](https://www.medtechdive.com/news/apple-fends-off-masimo-challenge-to-apple-watch-redesign/818158/?utm_source=openai))
Implications of the Court’s Decision
The dismissal of Masimo’s complaint signifies a substantial win for Apple, allowing the company to continue selling its redesigned Apple Watch models in the U.S. without the looming threat of import bans. While the blood oxygen monitoring feature remains disabled on these models for U.S. consumers, the court’s decision alleviates immediate legal pressures and potential disruptions to Apple’s smartwatch sales.
Masimo’s Position and Future Prospects
Despite this setback, Masimo retains the option to appeal to the U.S. Court of Appeals for the Federal Circuit by June 16, 2026. The company has been steadfast in its efforts to protect its intellectual property, as evidenced by the substantial jury verdict in its favor in 2025. However, the recent court decisions indicate a challenging path ahead for Masimo in its pursuit of further legal action against Apple.
Conclusion
The dismissal of Masimo’s complaint marks a critical juncture in the ongoing legal saga between the two companies. For Apple, it represents a reinforcement of its product strategy and a reduction in legal uncertainties surrounding its flagship wearable device. For Masimo, it underscores the complexities and challenges inherent in enforcing patent rights against a tech giant. As the June 16 appeal deadline approaches, the tech industry will be closely monitoring any further developments in this high-profile case.
